Terns Pharmaceuticals (TERN) Competitors $2.24 -0.09 (-3.65%) As of 11:14 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TERN vs. CALT, IOVA, SNDX, AUPH, SYRE, BGM, ELVN, MLYS, NRIX, and VIRShould you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Calliditas Therapeutics AB (publ) (CALT), Iovance Biotherapeutics (IOVA), Syndax Pharmaceuticals (SNDX), Aurinia Pharmaceuticals (AUPH), Spyre Therapeutics (SYRE), Qilian International Holding Group (BGM), Enliven Therapeutics (ELVN), Mineralys Therapeutics (MLYS), Nurix Therapeutics (NRIX), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry. Terns Pharmaceuticals vs. Calliditas Therapeutics AB (publ) Iovance Biotherapeutics Syndax Pharmaceuticals Aurinia Pharmaceuticals Spyre Therapeutics Qilian International Holding Group Enliven Therapeutics Mineralys Therapeutics Nurix Therapeutics Vir Biotechnology Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership. Do analysts recommend CALT or TERN? Calliditas Therapeutics AB (publ) presently has a consensus price target of $39.25, suggesting a potential downside of 1.88%. Terns Pharmaceuticals has a consensus price target of $18.38, suggesting a potential upside of 718.49%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Terns Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Do institutionals and insiders hold more shares of CALT or TERN? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 15.1% of Terns Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings and valuation, CALT or TERN? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Terns Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Terns Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Terns PharmaceuticalsN/AN/A-$90.21M-$1.13-1.99 Does the media refer more to CALT or TERN? In the previous week, Terns Pharmaceuticals had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Terns Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Terns Pharmaceuticals'average media sentiment score. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Terns Pharmaceuticals Neutral Which has more volatility & risk, CALT or TERN? Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.3, meaning that its stock price is 130% less volatile than the S&P 500. Is CALT or TERN more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Terns Pharmaceuticals' return on equity of -32.76% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Terns Pharmaceuticals N/A -32.76%-31.33% Does the MarketBeat Community favor CALT or TERN? Terns Pharmaceuticals received 15 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 59.15% of users gave Terns Pharmaceuticals an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Terns PharmaceuticalsOutperform Votes4259.15% Underperform Votes2940.85% SummaryTerns Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks. Remove Ads Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TERN vs. The Competition Export to ExcelMetricTerns PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$195.20M$6.51B$5.38B$7.14BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-1.896.7722.8217.35Price / SalesN/A188.62353.9684.30Price / CashN/A65.6738.1634.64Price / Book0.545.636.263.78Net Income-$90.21M$142.37M$3.21B$247.18M7 Day Performance-23.12%-11.25%-7.92%-7.74%1 Month Performance-36.04%-14.25%-2.85%-10.35%1 Year Performance-59.11%-18.14%3.82%-7.76% Terns Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TERNTerns Pharmaceuticals4.0374 of 5 stars$2.25-3.6%$18.38+718.5%-61.2%$195.20MN/A-1.8940CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180IOVAIovance Biotherapeutics4.1431 of 5 stars$3.63+2.5%$20.25+457.9%-76.8%$1.19B$164.07M-2.44500News CoverageGap DownSNDXSyndax Pharmaceuticals3.4653 of 5 stars$13.73+0.1%$36.20+163.7%-47.6%$1.18B$23.68M-3.78110Analyst UpgradePositive NewsGap DownAUPHAurinia Pharmaceuticals2.4486 of 5 stars$8.53+1.1%$11.50+34.8%+55.4%$1.17B$235.13M-56.86300SYRESpyre Therapeutics2.0569 of 5 stars$19.02+4.7%$50.86+167.4%-59.6%$1.15B$890,000.00-2.55100Gap DownBGMQilian International Holding GroupN/A$10.94-0.5%N/AN/A$1.06B$25.10M0.00298Positive NewsELVNEnliven Therapeutics2.6837 of 5 stars$22.46+6.5%$38.75+72.5%+7.7%$1.03BN/A-11.8250Gap DownMLYSMineralys Therapeutics2.9598 of 5 stars$16.17-4.1%$27.00+67.0%+4.9%$1.02BN/A-4.4428Analyst ForecastInsider TradeHigh Trading VolumeNRIXNurix Therapeutics1.8249 of 5 stars$13.34+2.7%$30.88+131.5%-28.0%$1.01B$54.55M-4.62300Upcoming EarningsAnalyst ForecastNews CoverageGap DownVIRVir Biotechnology3.5512 of 5 stars$7.20+3.9%$35.67+395.4%-38.5%$987.43M$63.71M-1.84580Gap Down Remove Ads Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Competitors Iovance Biotherapeutics Competitors Syndax Pharmaceuticals Competitors Aurinia Pharmaceuticals Competitors Spyre Therapeutics Competitors Qilian International Holding Group Competitors Enliven Therapeutics Competitors Mineralys Therapeutics Competitors Nurix Therapeutics Competitors Vir Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TERN) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
